Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 13 Sept 2019 |
| Genmab and Tempus Enter into Strategic Collaboration Agreement | 9 Sept 2019 |
| Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies | 30 Aug 2019 |
| Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan | 22 Aug 2019 |
| Genmab A/S has published its Articles of Association | 21 Aug 2019 |
| Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer | 21 Aug 2019 |